TahamtanAhmadiMD

PubMed

• 21 citations
  Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
  Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Kenshi Suzuki, Torben Plesner, Sung-S...> ;Journal of Clinical Oncology. 2023 Mar 10
• 79 citations
  Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
  Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres, Chan Y Cheah, Michael Roost Clausen, David Cunningham, Young Rok Do, Tatyana Feldman, Robin Gasiorowski, Wojc...> ;Journal of Clinical Oncology. 2023 Apr 20
• 24 citations
  Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
  Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria-Victoria Mateos, Tomer M ...> ;Journal of Clinical Oncology. 2023 Mar 10
• 28 citations
  Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
  Alexander Muik, Elena Garralda, Isil Altintas, Friederike Gieseke, Ravit Geva, Eytan Ben-Ami, Corinne Maurice-Dror, Emiliano Calvo, Patricia M LoRusso, Guzman Alonso, ...> ;Cancer Discovery. 2022 May 2
• 5 citations
  An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
  Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina B Schoedel, Saskia M Burm, Aras Toker, Theodora W Salcedo, Dennis Verzijl, David Eisel, Christian Grunwitz,...> ;Oncoimmunology. 2022 Jan 1
• 100 citations
  Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a ra...
  Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldsc...> ;The Lancet. Oncology. 2021 Oct 13
• 51 citations
  Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell tr...
  Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Sonja Zweegman, Hélène Caillon, Denis Caillot, Jill Cor...> ;The Lancet. Oncology. 2021 Oct 1
• 125 citations
  Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
  Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim Linton, Martine E.D. Chamuleau, David John Lewis, Anna Sureda Balari, David Cunningham, Robert...> ;Lancet. 2021 Sep 25
• 137 citations
  Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised,...
  Meletios A. Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena...> ;The Lancet. Oncology. 2021 Jun 1
• 66 citations
  Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
  Saad Z. Usmani, Hareth Nahi, Torben Plesner, Brendan M. Weiss, Nizar J. Bahlis, Andrew Belch, Peter M. Voorhees, Jacob P. Laubach, Niels W.C.J. van de Donk, Tahamtan A...> ;The Lancet. Haematology. 2020 Jun 1
• 557 citations
  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASS...
  Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot, Jill Cor...> ;Lancet. 2019 Jul 6
• 586 citations
  Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
  Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldsc...> ;The New England Journal of Medicine. 2019 May 29
• 12 citations
  Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ...
  Torben Plesner, Hendrik Tobias Arkenau, Monique C. Minnema, Mario Boccadoro, Philippe Moreau, Jamie Cavenagh, Aurore Perrot, Jacob P. Laubach, Jakub Krejcik, Tahamtan ...> ;British Journal of Haematology. 2019 Mar 31
• 23 citations
  Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
  Xiaoyu Yan, Pamela L. Clemens, Thomas A. Puchalski, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson, Torben Plesner, Kevin Liu, R...> ;Clinical Pharmacokinetics. 2018 Apr 1
• 142 citations
  Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
  Tineke Casneuf, Xu Steven Xu, Homer Adams, Amy Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W...> ;Blood Advances. 2017 Oct 24
• 62 citations
  Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Tr...
  Pamela L. Clemens, Xiaoyu Yan, Henk M. Lokhorst, Sagar Lonial, Nedjad Losic, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Kristen Lantz, Honghui Zhou, Thomas A. Pucha...> ;Clinical Pharmacokinetics. 2017 Aug 1
• 354 citations
  Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
  Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jonathan L. Kaufman, Jainulabdeen J. Ifthikharuddin, Brendan M. Weiss, Amrita Krishnan, Suzanne Lentz...> ;Blood. 2017 Aug 24
• 52 citations
  Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
  Xu Steven Xu, Xiaoyu Yan, Thomas A. Puchalski, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Torben Plesner, Kevin Liu, Imran Khan, Richard Jansson, Tahamtan Ahma...> ;Clinical Pharmacology and Therapeutics. 2017 Jun 1
• 1 citations
  Response to: Interference of daratumumab on the serum protein electrophoresis
  Christopher R. McCudden, Amy Axel, Dominique Slaets, Thomas Dejoie, Pamela L. Clemens, Sandy Frans, Jaime Bald, Torben Plesner, Joannes F M Jacobs, Niels W.C.J. van de...> ;Clinical Chemistry and Laboratory Medicine. 2017 Feb 1
• 92 citations
  Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulato...
  Saad Z. Usmani, Tahamtan Ahmadi, Yvette Ng, Annette Lam, Avinash Desai, Ravi Potluri, Maneesha Mehra> ;The Oncologist. 2016 Nov 1
• 84 citations
  Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
  Torben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Palumbo, Steen Lisb...> ;Blood. 2016 Oct 6
• 1015 citations
  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
  Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Mieczysław Komarnicki, Kenshi ...> ;The New England Journal of Medicine. 2016 Oct 5
• 1048 citations
  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
  Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria-Victoria Mateos, Tomer M ...> ;The New England Journal of Medicine. 2016 Aug 24
• 19 citations
  Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
  Evren Alici, Michael Chrobok, Johan Lund, Tahamtan Ahmadi, Imran Khan, Adil Doganay Duru, Hareth Nahi> ;British Journal of Haematology. 2016 Aug 1
• 624 citations
  Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
  Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W.C.J. van de Donk, Brendan M. Weiss, Tahamtan Ah...> ;Blood. 2016 Jul 21
• Join now to see all